Allarity to present Phase 2 stenoparib trial poster at ESMO congress
Allarity Therapeutics will present a Trial-in-Progress poster on its Phase 2 stenoparib study for platinum-resistant ovarian cancer at the ESMO Gynaecological Cancers Congress in Copenhagen. The presentation showcases the clinical rationale for the dual PARP and WNT pathway inhibitor ahead of upcoming clinical milestones.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day